Shares of Tempus AI surged 22% to $60.23 Wednesday after a landmark clinical trial handed the company an unexpected windfall of validation. A personalized mRNA cancer vaccine from Merck and Moderna succeeded in a late-stage clinical trial , and the technology underpinning that vaccine runs on genomic sequencing built by Personalis — the very company Tempus is acquiring for $1.5 billion to expand its capabilities in cancer monitoring .

  • The Sequencing Provider Behind the Headline Drug Now Belongs to Tempus. Personalis's genomic platform is used in the Merck-Moderna vaccine's clinical studies to sequence a patient's tumor and identify the unique mutations targeted by the treatment . The Phase 3 trial — enrolling over 1,100 melanoma patients — showed statistically significant improvements in recurrence-free survival, marking the first positive late-stage readout for an individualized mRNA cancer therapy in history . That transforms Personalis from a niche testing company into a critical supplier for what analysts estimate could generate more than $6 billion in annual sales in melanoma alone .

  • Wall Street Had Punished Tempus for the Deal — Until Now. TEM shares fell between 4% and 6.9% when the Personalis acquisition was announced , and Needham flagged the roughly 15.5x estimated 2027 sales multiple as steep versus peers . Wednesday's rally effectively erased that skepticism. If Personalis's sequencing technology becomes essential infrastructure for approved cancer vaccines, the $1.5 billion price tag looks less like a premium and more like an early-mover advantage in a market the companies estimate at $20 billion .

  • Tempus's Own Numbers Were Already Improving. Q2 revenue rose 22% year-over-year to $382.5 million , and the company raised its full-year 2026 revenue outlook to roughly $1.6 billion, expanded gross margin to 64%, and turned profitable . Adding Personalis's cancer-monitoring revenue — $22.4 million last quarter with clinical test volume up 33% — now comes with a far stronger growth narrative attached.

  • The Trial Is a Beginning, Not a Conclusion. The Phase 3 study will continue to assess overall survival, and Merck indicated it would begin talking to regulators "in the next few months" . Moderna is also studying the vaccine in lung cancer . Each new indication that advances would deepen demand for Personalis's sequencing — but approval timelines stretch years, and the companies have not yet released specific data . Tempus shareholders are pricing in a future that remains scientifically promising but commercially unproven.